Xeomin (incobotulinumtoxinA) / Merz Pharma - LARVOL DELTA

IncobotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy Evaluation of Lower Limb IncobotulinumtoxinA Efficacy (ELLIE) (MDS Congress 2026) - No abstract available

Clinical • Cerebral Palsy • CNS Disorders • Movement Disorders

Long-term dose-effect patterns with incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in cervical dystonia: multicenter real-world analysis (MDS Congress 2026) - No abstract available

Clinical • Real-world • Real-world evidence • CNS Disorders • Dystonia • Movement Disorders

IncobotulinumtoxinA to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 7-year Interim Results (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Targeted IncobotulinumtoxinA Injections into the Muscle of Riolan: A Novel Rescue Strategy for Refractory Apraxia of Lid Opening in Neurodegenerative Disorders (MDS Congress 2026) - No abstract available

CNS Disorders

PLATINUM US: A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: Merz North America, Inc. | Trial completion date: Jan 2028 ➔ Sep 2027 | Trial primary completion date: Oct 2026 ➔ Jun 2026

Trial completion date • Trial primary completion date

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU) (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: Merz Aesthetics GmbH | Trial completion date: Nov 2027 ➔ Aug 2027 | Trial primary completion date: Jan 2027 ➔ Oct 2026

Trial completion date • Trial primary completion date

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder (clinicaltrials.gov) - P2 | N=210 | Recruiting | Sponsor: Vensica Therapeutics Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Overactive Bladder

Botulinum toxin A for primary axillary hyperhidrosis: a narrative review. (PubMed, J Med Life) - "Comparative data indicate similar efficacy among onabotulinumtoxinA, incobotulinumtoxinA, and abobotulinumtoxinA when equivalent dosing and standardized mapping techniques are applied. Energy-based modalities-including microwave thermolysis and fractional microneedle radiofrequency-reduce sweating via device-mediated thermal targeting of eccrine glands and show variable comparative outcomes versus intradermal BoNT-A in durability, downtime, and cost. Overall, BoNT-A remains a well-supported first-line injectable therapy for PAH refractory to topical treatment, while further head-to-head and cost-effectiveness studies remain warranted."

Journal • Review • Dermatology

Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: Northwestern University | Trial completion date: Jun 2028 ➔ Sep 2028 | Initiation date: Jun 2026 ➔ Sep 2026 | Trial primary completion date: Jun 2028 ➔ Sep 2028

Trial completion date • Trial initiation date • Trial primary completion date • Erectile Dysfunction

UHNM has become the first NHS Trust in the UK to recruit a patient onto the MINT-C trial, with the Royal Stoke University Hospital currently the only UK centre taking part in the international study. (UHNM NHS Trust) - "The trial is evaluating a new type of botulinum toxin treatment which researchers hope could help reduce the frequency of migraine attacks while requiring fewer injections than existing therapies."

Trial status • Migraine

Reply to Ståhl et al. Comment on "Honndorf et al. Comparative Analytics and Pharmacodynamics of the Complex Protein-Free Botulinum Toxin Type A Formulations DaxibotulinumtoxinA, IncobotulinumtoxinA and RelabotulinumtoxinA. Toxins 2026, 18, 142". (PubMed, Toxins (Basel)) - "We appreciate the comment [...]."

Journal • PK/PD data

Efficacy and Safety of a Tailored Dosing Strategy with High-Dose IncobotulinumtoxinA at Flexible Injection Intervals for Cervical Dystonia: An Open-Label, Uncontrolled, Single-Arm Study in Japan. (PubMed, Neurol Int) - "IncobotulinumtoxinA was associated with improvements in symptoms and manageable safety profile at high doses and flexible injection intervals in Japanese patients with CD. While these findings suggest a potential treatment option for individualized dose optimization, the absence of a control group and the exploratory nature of the assessment in Group B necessitate cautious interpretation."

Journal • CNS Disorders • Dystonia • Gastrointestinal Disorder • Movement Disorders

IncobotulinumtoxinA Injection to Balance Eyebrows and Facial Shapes: A Review with Illustrative Clinical Examples. (PubMed, Toxins (Basel)) - "The assessment method aims for the best match between the individual facial shape and eyebrow form and position. This technique enables individualized modulation of eyebrow position and shape, improving facial balance while addressing dynamic upper facial rhytides, thereby promoting harmonious outcomes that preserve individual facial characteristics and providing an additional approach to conventional eyebrow enhancement techniques."

Journal • Review

Botulinum Toxin in Parkinson's Disease Tremor: A Critical Evaluation of the Evidence and Clinical Practice. (PubMed, Toxins (Basel)) - "The careful patient selection this approach requires helps the individual clinician and patient achieve tremor relief, but it departs from the unselected real-world PD population and introduces selection bias that makes a large, statistically representative cohort difficult to assemble. In well-selected patients at centers with the appropriate expertise, BoNT may be a clinically useful option, but routine adoption is not yet supported."

Journal • Review • CNS Disorders • Essential Tremor • Movement Disorders • Parkinson's Disease

Comment on Honndorf et al. Comparative Analytics and Pharmacodynamics of the Complex Protein-Free Botulinum Toxin Type A Formulations DaxibotulinumtoxinA, IncobotulinumtoxinA and RelabotulinumtoxinA. Toxins 2026, 18, 142. (PubMed, Toxins (Basel)) - "In their recent paper comparing three complexing protein-free botulinum toxin A products available on the market [...]."

Journal • PK/PD data

Benefits of Incobotulinumtoxin A in Pain, Spasticity and Functionality-A 5 Years Review. (PubMed, Toxins (Basel)) - "Promising functionality outcomes, especially in this group, warrant further, more comprehensive studies."

Journal • Retrospective data • Cardiovascular • Movement Disorders • Pain

BOTOX vs. XEOMIN for Chronic Migraine (clinicaltrials.gov) - P3 | N=128 | Recruiting | Sponsor: Naval Medical Center Camp Lejeune | Trial completion date: Aug 2026 ➔ Aug 2027 | Trial primary completion date: Feb 2026 ➔ Feb 2027

Trial completion date • Trial primary completion date • CNS Disorders • Migraine

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU) (clinicaltrials.gov) - P3 | N=300 | Active, not recruiting | Sponsor: Merz Aesthetics GmbH | Recruiting ➔ Active, not recruiting

Enrollment closed

One-day rejuvenation: a preliminary case series of a multimodal protocol combining Q-switched 1064 nm laser, botulinum toxin, and laser-assisted delivery of PDRN and retinoids. (PubMed, J Cosmet Laser Ther) - "To preliminarily evaluate the feasibility and clinical outcomes of a single-session protocol combining Q-switched (QS) 1064 nm laser, incobotulinumtoxinA, and laser-assisted drug delivery (LADD) of polydeoxyribonucleotide (PDRN) and retinoic acid...BoNT-A efficacy was clinically preserved throughout follow-up. This multimodal protocol appears to be a feasible and well-tolerated strategy for same-session facial rejuvenation without clinically compromising BoNT-A efficacy."

Journal • Aesthetic Medicine

Efficacy of IncobotulinumtoxinA (BoNT-A) Injections in Upper Limb Task-Specific and Position-Dependent Tremors. (PubMed, Mov Disord Clin Pract) - "Serial BoNT-A injections significantly improved handwriting and patient-reported physical function in TST and PDT."

Journal • Essential Tremor • Movement Disorders

A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Northwestern University | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date

Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) (clinicaltrials.gov) - P3 | N=220 | Active, not recruiting | Sponsor: Assistance Publique - Hpitaux de Paris | Recruiting ➔ Active, not recruiting

Enrollment closed • Atrial Fibrillation • Cardiovascular

Understanding Patient Diversity & Placebo Response in Post-Surgical/Traumatic Neuropathic Pain: Results from the PaiNT Proof-of-Concept Phase 2 Trial (EAN 2026) - "IncobotulinumtoxinA (incoBoNT-A, Xeomin®) may provide a promising local treatment of peripheral NP (PNP)... Improvements in ADP/NPSI in the PS/PTNP population were masked by very high placebo response. Treatment with incoBoNT-A is safe, but group heterogeneities make the comparison to placebo inconclusive. Careful patient selection is essential for future research."

Clinical • P2 data • Neuralgia • Pain

Efficacy & Safety of IncobotulinumtoxinA in Patients with Postherpetic Neuralgia: Results from the PaiNT Proof-of-Concept Phase 2 Trial (EAN 2026) - "The PaiNT proof-of-concept study demonstrated clinically meaningful results with a favourable tolerability profile in treatment of PHN with IncoBoNT-A, supporting further research potentially with higher dosages in this PNP indication."

Clinical • P2 data • Neuralgia • Pain • Peripheral Neuropathic Pain

Pattern Changes and Recurrent Remissions in Cervical Dystonia: Insights from a Long-Term Treated Case. (PubMed, Toxins (Basel)) - "Over time, treatment requirements decreased from higher initial doses (500-700 U abobotulinumtoxinA and up to 130 U onabotulinumtoxinA) to lower maintenance doses of 30-50 U incobotulinumtoxinA/onabotulinumtoxinA, with longer injection intervals and no obvious documented need for dose adjustment to maintain clinical responsiveness. This case highlights the coexistence of pattern changes and recurrent remissions within a single continuously followed patient over an unusually long period. Although a treatment-related mechanism remains speculative and alternative explanations cannot be excluded, the observation underscores the value of prolonged follow-up and individualized treatment strategies in CD."

Journal • CNS Disorders • Dystonia • Movement Disorders